Search alternatives:
significant genes » significant gender (Expand Search), significant benefits (Expand Search), significant changes (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
genes decrease » sizes decrease (Expand Search), teer decrease (Expand Search), greatest decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
significant genes » significant gender (Expand Search), significant benefits (Expand Search), significant changes (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
genes decrease » sizes decrease (Expand Search), teer decrease (Expand Search), greatest decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
-
81
-
82
Deterministic result of the base-case analysis.
Published 2024“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
Significantly Enriched Pathways.
Published 2025“…Pathway analysis revealed a marked decrease in expression within certain key metabolic pathways (such as the one-carbon pool by folate) in the NAFLD group, while expression in DNA repair-related pathways (such as non-homologous end joining) was significantly increased. …”
-
91
Defatting results in decreased gene expression of pro-inflammatory biomarkers.
Published 2020“…<p>Defatting of steatotic livers (DSL) results in significantly decreased gene expression of NF-κB and TNF-α compared to both the SL and LL groups. …”
-
92
-
93
-
94
-
95
-
96
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
97
-
98
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
99
-
100
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”